How many 8-K filings has Silence Therapeutics PLC filed?

Silence Therapeutics PLC (SLNCF) has 9 8-K (Current Event Report) filings on record, spanning Jan 2025 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Silence Therapeutics PLC 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Silence Therapeutics PLC 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Silence Therapeutics PLC (SLNCF) — 8-K Filings

All 8-K filings from Silence Therapeutics PLC. Browse 9 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (9)

Silence Therapeutics Announces CMO Departure, Appoints Interim — Dec 15, 2025 Risk: medium
Silence Therapeutics plc announced on December 14, 2025, the departure of its Chief Medical Officer, Dr. Anish Surpur. The company also reported the appointment
Silence Therapeutics Files 8-K — Oct 23, 2025 Risk: low
On October 23, 2025, Silence Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicat
Silence Therapeutics Announces Board and Officer Changes — Aug 14, 2025 Risk: medium
Silence Therapeutics plc announced on August 11, 2025, changes in its board of directors and executive officers. Specifically, the company reported the departur
Silence Therapeutics Files 8-K on Financials — Aug 7, 2025 Risk: low
Silence Therapeutics plc filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, as well as financial statements and exh
Silence Therapeutics Reports on Shareholder Vote Matters — Jun 27, 2025 Risk: low
Silence Therapeutics plc filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders as of June 26, 2025. The filing does not co
Silence Therapeutics plc Files 8-K Report — May 8, 2025 Risk: low
Silence Therapeutics plc filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibi
Silence Therapeutics Announces CMO Departure, Interim Appointment — May 6, 2025 Risk: medium
Silence Therapeutics plc announced on May 5, 2025, the departure of its Chief Medical Officer, Dr. Anish Bhatnagar, and the appointment of Dr. Gareth Baylis as
Silence Therapeutics Files 8-K on Financials — Feb 27, 2025 Risk: low
Silence Therapeutics plc filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation
Silence Therapeutics Files 8-K — Jan 2, 2025 Risk: low
On January 2, 2025, Silence Therapeutics plc filed an 8-K report to disclose information under Regulation FD. The filing does not contain specific details about

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX